Lonza Trims Portfolio To Nutrition, Pharma, Biotech; Equity Groups Acquire Specialty Business
Executive Summary
Private equity firms Bain Capital and Cinven Group Ltd. agree to acquire Lonza’s specialty ingredients business for $4.72Bn. Lonza says it will focus on its pharma, biotech and nutrition business, including a nutraceutical capsule manufacturing operation.